More Targretin, err...Rezulin news:
Warner-Lambert Rezulin gets new indications
MORRIS PLAINS, N.J., Aug 4 (Reuter) - Warner-Lambert Co said on Monday the U.S. Food and Drug Administration cleared Rezulin, its therapy for type 2 diabetes, for use alone or in combination with agents known as sulfonylureas.
Studies have shown that a substantial number of patients taking Rezulin as initial therapy or in combination with sulfonylureas or insulin can reach American Diabetes Association targets for blood glucose control, Warner said.
Rezulin reduces a patient's insulin resistance by a nuclear mechanism, thereby enabling the body to more efficiently use the insulin it produced or which was injected, Warner-Lambert said.
Unlike sulfonylureas, Rezulin does not stimulate insulin secretion, Warner said. The addition of Rezulin to a sulfonylurea has a synergistic effect because both agents act to improve glucose tolerance by complementary mechanisms.
``There is an impressive synergy between Rezulin and these older agents,'' Gerald Bernstein, associate clinical professor of medicine, Albert Einstein College of Medicine, said.
It could also be used alone, as an adjunct to diet and exercise to lower blood glucose levels in patients with type 2 diabetes, the company said. |
